MedTrace Logo

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults

NCT00712803 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2013-01-03

No results posted yet for this study

Summary

Dengue fever, which is caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety of and immune response to a new dengue virus vaccine in healthy adults.

Conditions

  • Dengue

Interventions

BIOLOGICAL

rDEN3-3'D4delta30

Live attenuated 10\^3 dose of rDEN3-3'D4delta30 vaccine.

BIOLOGICAL

rDEN3-3'D4delta30

Live attenuated 10\^5 dose of rDEN3-3'D4delta30 vaccine.

BIOLOGICAL

rDEN3-3'D4delta30

Live attenuated 10\^1 dose of rDEN3-3'D4delta30 vaccine.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Anna Durbin, MD · Center for Immunization Research (CIR), Johns Hopkins School of Public Health

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00712803 on ClinicalTrials.gov